Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

17.08.2023 | short review

ASCO 2023: new treatment options in CNS tumors

Invited short review

verfasst von: Dr. Josef Pichler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

Practice-changing therapy for IDH1/2–mutant diffuse glioma was presented at the meeting. Vorasidenib as an oral, brain penetrant, dual inhibitor of mutant IDH1/2 showed very promising results in the phase 3 INDIGO study. Other new treatment approaches including vaccines, immunotherapy and targeted therapy in rare von Hippel–Lindau-associated cerebral hemangioblastomas have shown progress in neuro-oncology.
Vorheriger Artikel Supportive management
Nächster Artikel Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
Literatur
1.
2.
Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.CrossRefPubMed
3.
4.
5.
Wakimoto H, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898–909.CrossRefPubMedPubMedCentral
6.
7.
ClinicalTrials.gov Identifier: NCT03922555; ASTX727 in Recurrent/Progressive Non enhancing IDH Mutant Gliomas
8.
ClinicalTrials.gov Identifier: NCT05406700 Niraparib In Recurrent IDH 1/2 Gliomas
Metadaten
Titel
ASCO 2023: new treatment options in CNS tumors
Invited short review
verfasst von
Dr. Josef Pichler
Publikationsdatum
17.08.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00915-z

Weitere Artikel der Ausgabe 4/2023

Prostate cancer special—part 1

  • editorial

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

  • case report

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

  • short review

Editorial

  • editorial

Supportive management

  • editorial

Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors

  • Open Access
  • short review